Could inflammation predict who benefits from magic mushroom therapy?

NCT ID NCT07164755

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study examines blood samples from 46 people with treatment-resistant depression who took psilocybin in a previous trial. Researchers will measure markers of inflammation (cytokines and mRNA) to see if they relate to how well the treatment worked. The goal is to understand whether inflammation levels before or after treatment can predict who gets better, which could help personalize psychedelic therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict who will benefit from psilocybin therapy and point toward new ways to treat depression by targeting inflammation.
What could go wrong
This is a small, observational analysis of existing samples, not a new treatment trial. It may not find clear links between inflammation and depression outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • King's College London Institute of Psychiatry, Psychology and Neuroscience

    London, SE5 8AF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.